EchoIQ Strengthens Leadership Team and Clinical Advisory Network to Accelerate Next Phase of Commercial Growth and U.S. FDA Initiatives
SYDNEY, June 24, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) ("Echo IQ" or "the Company") today announced two key appointments to its executive leadership team and broader clinical advisory network to support the next phase of commercial growth for its EchoSolv platform, expand its presence within the U.S. healthcare market and advance regulatory initiatives with the U.S. FDA. Matthew Dodds has been appointed Chief Financial Officer, effective 24 June
SYDNEY, June 24, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) ("Echo IQ" or "the Company") today announced two key appointments to its executive leadership team and broader clinical advisory network to support the next phase of commercial growth for its EchoSolv platform, expand its presence within the U.S. healthcare market and advance regulatory initiatives with the U.S. FDA. Matthew Dodds has been appointed Chief Financial Officer, effective 24 June 2026, and Dr. Vinod Thourani, internationally recognised as one of the foremost authorities in structural heart disease, heart valve therapies and cardiovascular surgery, has been appointed Clinical Advisor.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.